Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Adipose Progenitor Cell Secretion of GM-CSF and MMP9 Promotes a Stromal and Immunological Microenvironment That Supports Breast Cancer Progression.

Reggiani F, Labanca V, Mancuso P, Rabascio C, Talarico G, Orecchioni S, Manconi A, Bertolini F.

Cancer Res. 2017 Sep 15;77(18):5169-5182. doi: 10.1158/0008-5472.CAN-17-0914. Epub 2017 Jul 28.

2.

Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case report.

Gruszka AM, Rabascio C, Cannella L, Sammassimo S, Andreola G, Gregato G, Faretta M, Calleri A, De Molfetta R, Pruneri G, Bertolini F, Alcalay M.

Sci Rep. 2015 Oct 6;5:14829. doi: 10.1038/srep14829.

3.

Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine.

Curigliano G, Bagnardi V, Bertolini F, Alcalay M, Locatelli MA, Fumagalli L, Rabascio C, Calleri A, Adamoli L, Criscitiello C, Viale G, Goldhirsch A.

Breast. 2015 Jun;24(3):263-71. doi: 10.1016/j.breast.2015.02.036. Epub 2015 Mar 12.

PMID:
25772326
4.

Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease.

Pastano R, Dell'Agnola C, Bason C, Gigli F, Rabascio C, Puccetti A, Tinazzi E, Cetto G, Peccatori F, Martinelli G, Lunardi C.

Int Immunol. 2012 Sep;24(9):583-91. doi: 10.1093/intimm/dxs061. Epub 2012 Jul 6.

PMID:
22773152
5.

Who should be really considered as a poor mobilizer in the plerixafor era?

Andreola G, Vanazzi A, Radice D, Babic A, Rabascio C, Negri M, Martinelli G, Laszlo D.

Transfus Apher Sci. 2012 Aug;47(1):27-32. doi: 10.1016/j.transci.2012.03.004. Epub 2012 Apr 4.

PMID:
22480954
6.

Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.

Andreola G, Babic A, Rabascio C, Negri M, Martinelli G, Laszlo D.

Eur J Haematol. 2012 Feb;88(2):154-8. doi: 10.1111/j.1600-0609.2011.01719.x. Epub 2011 Nov 17.

PMID:
21992403
7.

Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia.

Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Pinto A, Negri M, Martinelli G.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):130-2. doi: 10.3816/CLML.2011.n.029.

PMID:
21454213
8.

Circulating perivascular progenitors: a target of PDGFR inhibition.

Mancuso P, Martin-Padura I, Calleri A, Marighetti P, Quarna J, Rabascio C, Braidotti P, Bertolini F.

Int J Cancer. 2011 Sep 15;129(6):1344-50. doi: 10.1002/ijc.25816. Epub 2011 Apr 13.

9.

A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy.

Bassi S, Rabascio C, Nassi L, Steffanoni S, Babic A, Bertazzoni P, Gigli F, Antoniotti P, Orlando L, Sammassimo S, Quarna J, Negri M, Martinelli G.

Transfus Apher Sci. 2010 Dec;43(3):321-326. doi: 10.1016/j.transci.2010.10.001. Epub 2010 Oct 30.

PMID:
21036667
10.

Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer.

Bono A, Bianchi P, Locatelli A, Calleri A, Quarna J, Antoniott P, Rabascio C, Mancuso P, Andreoni B, Bertolini F.

Cancer Biol Ther. 2010 Oct 1;10(7):682-5. Epub 2010 Oct 1.

PMID:
20676027
11.

Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients.

Bertazzoni P, Rabascio C, Gigli F, Calabrese L, Radice D, Calleri A, Gregato G, Negri M, Liptrott SJ, Bassi S, Nassi L, Sammassimo S, Laszlo D, Preda L, Pruneri G, Orlando L, Martinelli G.

Leuk Lymphoma. 2010 Aug;51(8):1485-93. doi: 10.3109/10428194.2010.495799.

PMID:
20578816
12.

Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.

Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, Pruneri G, Radice D, Pinto A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G.

J Clin Oncol. 2010 May 1;28(13):2233-8. doi: 10.1200/JCO.2009.23.6315. Epub 2010 Apr 5.

PMID:
20368573
13.

Blood-based biomarkers for the optimization of anti-angiogenic therapies.

Rabascio C, Bertolini F.

Cancers (Basel). 2010 May 28;2(2):1027-39. doi: 10.3390/cancers2021027.

14.

Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.

Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, Colleoni M, Bertolini F.

Clin Cancer Res. 2009 Dec 15;15(24):7652-7657.

15.

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.

Lemoli RM, Salvestrini V, Bianchi E, Bertolini F, Fogli M, Amabile M, Tafuri A, Salati S, Zini R, Testoni N, Rabascio C, Rossi L, Martin-Padura I, Castagnetti F, Marighetti P, Martinelli G, Baccarani M, Ferrari S, Manfredini R.

Blood. 2009 Dec 10;114(25):5191-200. doi: 10.1182/blood-2008-08-176016.

PMID:
19855080
16.

Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.

Rabascio C, Laszlo D, Andreola G, Saronni L, Radice D, Rigacci L, Fabbri A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G.

Leuk Res. 2010 Apr;34(4):454-7. doi: 10.1016/j.leukres.2009.07.002. Epub 2009 Aug 3.

PMID:
19647871
17.

Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.

Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita AJ, Saronni L, Cheng JB, Shalinsky DR, Heymach JV, Bertolini F.

Clin Cancer Res. 2009 Jan 1;15(1):267-73. doi: 10.1158/1078-0432.CCR-08-0432. Erratum in: Clin Cancer Res. 2015 Jun 1;21(11):2652.

18.

Is there a role for 'modified VAD' in the treatment of multiple myeloma?

Agazzi A, Sammassimo S, Laszlo D, Liptrott S, Cascio R, Alietti A, Rabascio C, Mancuso P, Pruneri G, Martinelli G.

Ecancermedicalscience. 2009;3:136. doi: 10.3332/ecancer.2009.136. Epub 2009 Jun 4.

19.

Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.

Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G, Shultz LD, Bertolini F.

Int J Cancer. 2008 Nov 1;123(9):2222-7. doi: 10.1002/ijc.23772.

20.

Circulating endothelial cell number and viability are reduced by exposure to high altitude.

Mancuso P, Peccatori F, Rocca A, Calleri A, Antoniotti P, Rabascio C, Saronni L, Zorzino L, Sandri MT, Zubani A, Bertolini F.

Endothelium. 2008 Jan-Feb;15(1):53-8. doi: 10.1080/10623320802092344.

PMID:
18568945
21.

A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer.

Ferrucci PF, Rabascio C, Gigli F, Corsini C, Giordano G, Bertolini F, Martinelli G.

Int J Oncol. 2007 Apr;30(4):955-62.

PMID:
17332935
22.

Chlorambucil - rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: a clinical and biological analysis.

Laszlo D, Rabascio C, Andreola G, Pruneri G, Raia V, Calabrese L, Radice D, Saronni L, Martinelli G.

Leuk Lymphoma. 2007 Feb;48(2):437-8. No abstract available.

PMID:
17325914
23.

Strategies to investigate circulating endothelial cells in cancer.

Mancuso P, Rabascio C, Bertolini F.

Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5-6):503-6. Review.

24.

Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer.

Ferrucci PF, Rabascio C, Mazzetta C, Cocorocchio E, Agazzi A, Vanazzi A, Cinieri S, Peccatori FA, Paolucci M, Bertolini F, Martinelli G.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6039-46.

25.

Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells.

Rabascio C, Muratori E, Mancuso P, Calleri A, Raia V, Foutz T, Cinieri S, Veronesi G, Pruneri G, Lampertico P, Iavarone M, Martinelli G, Goldhirsch A, Bertolini F.

Cancer Res. 2004 Jun 15;64(12):4373-7.

26.

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat.

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

Eur J Haematol. 2004 Apr;72(4):264-7.

PMID:
15089764
27.

Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34- human stem cells.

Lemoli RM, Bertolini F, Petrucci MT, Gregorj C, Ricciardi MR, Fogli M, Curti A, Rabascio C, Pandolfi S, Ferrari S, Foá R, Baccarani M, Tafuri A.

Br J Haematol. 2003 Nov;123(4):720-9. Erratum in: Br J Haematol. 2004 Jan;124(2):256. Rabascio, Cristina [corrected to Rabascio, Christina]; Fo, Robin [corrected to Foá, Robin].

PMID:
14616978
28.

In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue.

Dell'Agnola C, Rabascio C, Mancuso P, Capillo M, Pruneri G, Gobbi A, Minucci S, Ronzoni S, Volorio S, Calabrese L, Tradati N, Martinelli G, Shultz L, Bertolini F.

Exp Hematol. 2002 Aug;30(8):905-14.

PMID:
12160842
29.

CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.

Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, Gobbi A, Pruneri G, Martinelli G.

Cancer Res. 2002 Jun 1;62(11):3106-12.

30.

Supplemental Content

Loading ...
Support Center